Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

200868 citationsJournal Article

Authors

RNF has improved overall immunogenicity and safety profiles compared with the original formulation.

Good health and well-being

Published in: Multiple Sclerosis Journal

Volume 15, Issue 2, pp. 219-228

Field-Weighted Citation Impact: 6.38